AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Lexigen Signs On As 19th PER.C6 Licensee.(Brief Article)
2002 FEB 13 - (NewsRx.com & NewsRx.net) -- Dutch antibody and vaccine company Crucell (CRXL) has granted Boston-based Lexigen Pharmaceuticals Corp. a nonexclusive license for its proprietary human cell system PER.C6.
Under the terms of the agreement, Lexigen will use PER.C6 for research and clinical development of therapeutics in the field of oncology. Crucell will receive upfront and annual payments, while Lexigen has an option for a commercial license. Further financial details were not disclosed.
According to Crucell's CEO Dinko Valerio, the deal ...
- Crucell and Innogenetics Announce PER.C6 Deal for the Development And...
- Press release article from: PR Newswire January 23, 2002 700+ words
...disclosed. Crucell's CEO Dinko...vaccines and gene therapy, this deal...vaccines and gene therapy products...PER.C6, Crucell and Innogenetics...production of gene therapy products and viral vectors. Crucell has been listed...
- Crucell Announces First Quarter Results.
- Press release article from: PR Newswire May 8, 2001 700+ words
...license agreement with Crucell. * Executed a licensing...CEGE), a leading gene therapy company focused on the...therapies, for access to Crucell's PER.C6 technology...DirectGene has clinical gene therapy development programs...clinical batches at Crucell's Good Manufacturing...
- PER.C6 Manufacturing Services Available in United States; Crucell Enters Into...
- Press release article from: PR Newswire January 10, 2002 700+ words
...services for vaccine and gene therapy products" said Crucell's CEO Dinko Valerio...production of vaccine and gene therapy products. Crucell's eighteen PER.C6 licensees...Multiple vaccine and gene therapy clinical trials with PER...
- Lexigen Signs On as Crucell's 19th PER.C6 Licensee.
- Press release article from: PR Newswire January 15, 2002 700+ words
...disclosed. According to Crucell's CEO Dinko Valerio...the production of gene therapy and vaccine products...safety qualities." Crucell's nineteen PER...the production of gene therapy products and viral vectors. Crucell has been listed...
- Crucell Presents AdVac(TM), A New Improved Vaccine Technology.
- Press release article from: PR Newswire June 1, 2001 700+ words
...1 /PRNewswire/ -- Crucell N.V. (Nasdaq: CRXL...American Society for Gene Therapy (ASGT) in Seattle...development program, Crucell has developed a new...on diseased cells. Crucell's two broadly applicable...therapeutic proteins and gene therapy products. The second...
- Crucell Signs Up Another PER.C6 Customer, Enters Deal With GSK.(GlaxoSmithKline...
- Magazine article from: BIOWORLD Today Pihl-Carey, Karen August 16, 2004 700+ words
...for proteins and antibodies, Crucell has alliances with other contract...based recombinant vaccines and gene therapy products, and with Novavax...production of classical vaccines. Crucell started as a gene therapy company in 1993 under the name...
- Crucell Signs Up Another PER.C6 Customer, Enters Deal With GSK.
- Magazine article from: BIOWORLD Today November 3, 2009 700+ words
...for proteins and antibodies, Crucell has alliances with other contract...based recombinant vaccines and gene therapy products, and with Novavax...production of classical vaccines. Crucell started as a gene therapy company in 1993 under the name...
- Crucell Appoints VP Development and Regulatory Affairs.
- Press release article from: PR Newswire January 17, 2002 700+ words
...antibodies every single year. Crucell also plays an essential role...the exclusive rights to use Crucell's PER.C6 human cell system...industry for the production of gene therapy products and viral vectors. Crucell has been listed on the NASDAQ...
Source: HighBeam Research, Lexigen Signs On As 19th PER.C6 Licensee.(Brief Article)